| ²é¿´: 941 | »Ø¸´: 4 | |||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õßsheepdawn½«ÔùËÍÄú 10 ¸ö½ð±Ò | |||
sheepdawnľ³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÊÕµ½¡°Elsevier Publishing Opportunity¡±µÄÓʼþ£¬²»ÖªµÀʲôÒâ˼ ÒÑÓÐ1È˲ÎÓë
|
||
|
ÊÕµ½Elsevier·¢µÄ¡°Elsevier Publishing Opportunity¡±µÄÓʼþ£¬²»ÖªµÀʲôÒâ˼£¬Çë¸÷λ´óÉñ½â´ðһϠÓʼþÄÚÈÝÈçÏ Dear Dr. xxx, I recently read your article ¡°xxx¡± in Frontiers. I am writing to you based on your expertise as part of a new initiative that I am working on with Elsevier to publish concise books and e-books on timely, innovative, and focused topics spanning bioscience and translational medicine specialties. Specifically, I am looking for someone to assume the role of Editor for a book project. An expansion of your article to include a comprehensive overview of the area would be a perfect topic. The book may include an overview of the scientific background, the latest research in the area, the translational effect of research on clinical practice, as well as show new research areas for the future. The intended audience would be researchers with crossover for clinicians. While this is a preferred topic, I am also open to discussing other specialized topics if this does not have continued interest for you. The final product will contain approximately 200-300 printed pages (up to 10-15 chapters), and will be available in print as well as e-book format with inclusion on Elsevier¡¯s Biomedical Research ScienceDirect platform. There will be an 8% royalty as payment to you as editor for your work. Please let me know whether you may be interested in leading this project as the Editor and if not, if anybody appropriate comes to mind. Thank you, and I look forward to hearing from you soon. ÒòΪ֮ǰÔÚFrontiers·¢±íÁËһƪÁÙ´²Ñо¿µÄÎÄÕ£¬µ¼Ê¦ÊÕµ½Õâ¸öÓʼþ£¬Òâ˼ÊÇÒªÈÃÎÒÃÇ×÷Ϊ±à¼À´¸ºÔðÒ»¸öÎÒÃǸÐÐËȤµÄÑо¿Ö÷Ì⣬×îºó×÷ΪͼÊé³ö°æÂ𣿠±à¼²»ÊÇÒ»°ãÈËÄܸɵİɣ¬µ¼Ê¦ÎÊÎÒÕâ¸öÓÐÎÞ±ØÒª£¬ÎÒÌý×ÅÕ¦¸Ð¾õÕâô²»¿¿Æ×ÄØ£¬Óж®µÄ´óÀпÉÒÔÖ¸µãÒ»ÏÂÂð£¿Ð»Ð» |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ£¬³õÊԳɼ¨350Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ4È˻ظ´
323·Ö£¨¼ÆËã»úÊÓ¾õºÍ´óÄ£ÐÍÏîÄ¿£©ÄÜÖ±½ÓÉÏÊÖ
ÒѾÓÐ3È˻ظ´
311·Ö 22408 Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
320·ÖÈ˹¤ÖÇÄܵ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸Ö£´ó0705Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0703»¯Ñ§
ÒѾÓÐ10È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
306·Ö²ÄÁÏÓ뻯¹¤Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ11È˻ظ´
chaodanming
ľ³æ (Ö°Òµ×÷¼Ò)
- Ó¦Öú: 19 (СѧÉú)
- ½ð±Ò: 9036.5
- É¢½ð: 8969
- ºì»¨: 25
- Ìû×Ó: 4007
- ÔÚÏß: 651.7Сʱ
- ³æºÅ: 2512920
- ×¢²á: 2013-06-18
- ÐÔ±ð: GG
- רҵ: ¹¦ÄÜÓëÖÇÄܸ߷Ö×Ó
|
Õâ¾ÍÊÇÒ»¸öÀ¬»øÓʼþ¡£µ±È»£¬ÊÂÇé±¾ÉíÊÇÕæÊµµÄ¡£µ«Èç¹ûÄã°´ËûµÄÒªÇóÈ¥×ö£¬ºÄʱ·ÑÁ¦£¬×îÖÕ¿ÉÒÔ³öÒ»±¾µç×ÓÊé¡£µ«ÓëÄãËù¸¶³öµÄ²»³É±ÈÀý£¬³öÊéµÄϸ½ÚÌ«¶àÁË£¬·Ç³£·±Ëö¡£ ·¢×ÔСľ³æAndroid¿Í»§¶Ë |

2Â¥2022-12-12 05:49:58
sheepdawn
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2674.1
- É¢½ð: 1733
- ºì»¨: 3
- Ìû×Ó: 244
- ÔÚÏß: 154.6Сʱ
- ³æºÅ: 1004168
- ×¢²á: 2010-04-23
- ÐÔ±ð: GG
- רҵ: ΢ÉúÎïÉúÀíÓëÉúÎﻯѧ
3Â¥2022-12-12 08:48:46
nono2009
³¬¼¶°æÖ÷ (ÎÄѧ̩¶·)
No gains, no pains.
-

ר¼Ò¾Ñé: +21105 - SEPI: 10
- Ó¦Öú: 28684 (Ժʿ)
- ¹ó±ö: 513.911
- ½ð±Ò: 2555230
- É¢½ð: 27828
- ºì»¨: 2148
- ɳ·¢: 66666
- Ìû×Ó: 1602255
- ÔÚÏß: 65200.9Сʱ
- ³æºÅ: 827383
- ×¢²á: 2009-08-13
- ÐÔ±ð: GG
- רҵ: ¹¤³ÌÈÈÎïÀíÓëÄÜÔ´ÀûÓÃ
- ¹ÜϽ: ¿ÆÑмҳﱸίԱ»á
4Â¥2022-12-13 11:53:52
sheepdawn
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2674.1
- É¢½ð: 1733
- ºì»¨: 3
- Ìû×Ó: 244
- ÔÚÏß: 154.6Сʱ
- ³æºÅ: 1004168
- ×¢²á: 2010-04-23
- ÐÔ±ð: GG
- רҵ: ΢ÉúÎïÉúÀíÓëÉúÎﻯѧ
5Â¥2022-12-16 08:10:15














»Ø¸´´ËÂ¥